Research Nester released a report titled “Immuno-Oncology Treatment Market: Global Demand Analysis & Opportunity Outlook 2027” which delivers detailed overview of the global immuno-oncology treatment market in terms of market segmentation by product, by administration, by end user and by region.
Further, for the in-depth analysis, the report encompasses the industry growth drivers, restraints, supply and demand risk, market attractiveness, BPS analysis and Porter’s five force model.
Immuno-oncology treatment is a form of targeted therapy that works by stimulating the body’s own immune system in order to generate a response against the target cancer cells. The market for immune-oncology treatment is projected to grow by a CAGR of 12.68% during the forecast period, i.e., 2020-2027. Moreover, the market is anticipated to attain a value of USD 157,230.48 million by the year 2027. This growth can be attributed to the growing advancements and innovations in the industry which is predicted to result in new treatment methods that are highly effective. The market is segmented by product, by administration, by end user and by region. Based on administration, the market is bifurcated into standalone therapy and combination therapy, out of which, the combination therapy segment is projected to occupy the largest portion in the market as a result of growing number of approved treatments and higher effectiveness of the therapy.
On the basis of region, the market is segmented into North America, Latin America, Europe, Asia-Pacific and Middle East and Africa, out of which, the largest share during the forecast period is estimated to be occupied by the market in North America. The rising investments in the healthcare industry by various government and private institutions and organizations so as to maintain high quality healthcare services and products is predicted to be responsible for the noteworthy growth of the market in this region.
Increasing Incidences Of Cancer To Substantially Drive The Market Growth
As per the World Health Organization, the global cancer burden is estimated to have risen to 18.1 million new cases and 9.6 million deaths in 2018. The rising cases of cancer is the major factor anticipated to support the market growth in the coming years. The growing incidence of this disorder can be attributed to ageing global population as well as increasing exposure to various cancer risk factors. This is anticipated to significantly raise the demand for immune-oncology treatments in the market. However, the limited access to healthcare, especially among the cancer patients residing in low- and middle-income countries, is estimated to become a growth barrier for the market over the forecast period.
This report also provides the existing competitive scenario of some of the key players of the global immuno-oncology treatment market which includes company profiling of F. Hoffmann-La Roche Ltd (SWX: ROG), Merck & Company, Inc. (NYSE: MRK), AstraZeneca Plc. (LON: AZN), Novartis (SWX: NOVN), Amgen Inc. (NASDAQ: AMGN), Pfizer Inc. (NYSE: PFE), Bristol-Myers Squibb Company (NYSE: BMY), Eli Lilly and Company (NYSE: LLY), Janssen and GlaxoSmithKline plc. (LON: GSK). The profiling enfolds key information of the companies which encompasses business overview, products and services, key financials and recent news and developments. On the whole, the report depicts detailed overview of the global immuno-oncology treatment market that will help industry consultants, equipment manufacturers, existing players searching for expansion opportunities, new players searching possibilities and other stakeholders to align their market centric strategies according to the ongoing and expected trends in the future.
